Cytogenetic Studies in Leukemia Patients

Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (non-APL) leukemia: a Southwest Oncology study (S9007)

TH Norwood;HM Gundacker;ML Slovak;HP Erba;FR Appelbaum Proc of the ASH, Blood 108:#808, 2006.

21q22-balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop

ML Slovak;V Bedell;L Popplewell;DA Arber;C Schoch;R Slater Genes Chromosomes & Cancer 33:379-394

Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study

SR Wolman;H Gundacker;FR Appelbaum;ML Slovak Blood 100(1):29-35

Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in myeloid leukemia patients in Southwest Oncology Group (SWOG) trials.

SR Wolman;H Gundacker;ML Slovak;FR Appelbaum Proc of the American Society of Clinical Oncology 20:282a(#1125)

Prognostic implication of additional cytogenetic aberrations in denovo acute myeloid leukemia (AML) with t(15:17), t(8;21) or inv(16)/t(16;16).

PH Wiernik;H Kim;H Gundacker;G Dewald;ML Slovak;E Paietta;FR Appelbaum;MS Tallman Blood 98(11):457a(#1913)

The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.

ML Slovak;H Gundacker;SR Wolman;FR Appelbaum American Journal of Human Genetics 69(4):232(#285)

Report on workshop regarding leukemia studies by SWOG cytogenetic laboratories.

G Kinzie The Journal of the Association of Genetic Technologists 24(2):44-46

Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

CP Leith;KJ Kopecky;J Godwin;T McConnell;ML Slovak;I Chen;DR Head;FR Appelbaum;CL Willman Blood 89(9):3323-3329

Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.

DE Banker;M Groudine;T Norwood;FR Appelbaum Blood 89(1):243-255

Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia.

L Pearson;CP Leith;MH Duncan;IM Chen;T McConnell;K Trinkaus;K Foucar;CL Willman Leukemia 10:1274-1282

Correlation of PML-RARa mRNA transcript type with morphology, cytogenetics and clinical parameters in actue promyelocytic leukemia.

D Viswanatha;KJ Kopecky;K Doss;C Rankin;DR Head;RE Magenis;FR Appelbaum;CL Willman Intl Academy of Pathology Book of Abstracts :125A(#730)

Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia.

T Nakamura;DA Largaespada;MP Lee;LA Johnson;K Ohyashiki;K Toyama;SJ Chen;CL Willman;IM Chen;AP Feinberg;NA Jenkins;NG Copeland;JD Shaughnessy Jr Nature Genetics 12:154-158

Acute myeloid leukemia in the elderly: high frequency of trilineage dyspoiesis suggests that elderly AML is biologically similar to AML arising secondary to myelodysplasia.

CP Leith;KJ Kopecky;CL Willman;M Slovak;T McConnell;J Godwin;I Chen;FR Appelbaum;DR Head Blood 88(10)Suppl:559a(#2225)

Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1).

CL Willman Leukemia 10(Suppl.1):S33-S35

A subgroup of elderly AML patients with a high complete remission rate can be defined.

ML Slovak;KJ Kopecky;T McConnell;CP Leith;J Godwin;IM Chen;C Rankin;DR Head;F Appelbaum;CL Willman Trends in Onco-Hematology 4(2):34-35

Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology

DR Head;F Behm;S Raimondi;A Carroll;M Slovak;E Magenis;C Willman;J Licht;A Scott;MV Gresik;J Downing;D Butler;T Motroni International Academy of Pathology Book of Abstracts :112A(#651)

Heterogeneity in CBFB/MYH11 fusion messages encoded by inv(16) and t(16;16) in acute myelogenous leukemia (AML)

J Downing;S Shurtleff;S Meyers;S Hiebert;S Raimondi;D Head;C Willman;S Wolman;A Carroll;F Behm;F Collins;P Liu International Academy of Pathology Book of Abstracts :109A(#630)

Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line

M Saito;K Helin;MB Valentine;BB Griffith;CL Willman;E Harlow;AT Look Genomics 25:130-138

Heterogeneity in CBF'/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia

SA Shurtleff;S Meyers;SW Hiebert;SC Raimondi;D Head;CL Willman;SR Wolman;ML Slovak;AJ Carroll;F Behm;MG Hulshof;TA Motroni;T Okuda;P Liu;FS Collins;JR Downing Blood 85(12):3695-3703

Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.

B Mehrotra;TI George;K Kavanau;H Avet-Loiseau;D Moore II;Cl Willman;ML Slovak;S Atwater;DR Head;MG Pallavicini Blood 86(3):1139-1147

Multidrug resistance (MDR1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).

CP Leith;KJ Kopecky;IM Chen;JE Godwin;FR Appelbaum;DR Head;CL Willman Leukemia 9(3):535(#O31)

CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)

AA Scott;KJ Kopecky;TM Grogan;DR Head;FA Troy, II;J Mullen;J Ya;FR Appelbaum;KS Theil;CL Willman Intl Academy of Pathology 120A(#695)/Lab Investigation 70(1):120A(#695)

The detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization.

PA Scalamogna;KS Theil American Journal of Clinical Pathology 101(3):377(#8)

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3

AA Scott;DR Head;KJ Kopecky;FR Appelbaum;KS Theil;MR Grever;I-M Chen;MH Whittaker;BB Griffith;JD Licht;S Waxman;MM Whalen;AD Bankhurst;LC Richter;TM Grogan;CL Willman Blood 84(1):244-255

Trisomy 8: A primary cytogenetic anomaly in leukemia?

SR Wolman;ML Slovak;CL Willman;FR Appelbaum;RE Magenis Blood 84(10)(Suppl.1):308a(#1219)

Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML.

H Avet-Loiseau;K Thiel;T McConnell;CL Willman;S Atwater;MG Pallavicini Blood 84(10)(Suppl.1)(#2380):599a

Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia (AML).

L Pearson;CP Leith;I-M chen;MH Duncan;T McConnell;K Theil;K Foucar;CL Willman Blood 84(10)(Suppl.1)(#172):46a

Acute promyelocytic leukemia associated wit t(11;17) is a discrete syndrome that fails to respond to retinoic acid.

JD Licht;C Chomienne;A Goy;A Chen;AA Scott;DR Head;JL Michaux;Y Wu;A DeBlasio;WH Miller Jr;AD Zelenetz;CL Willman;Z Chen;A Zelent;E Macintyre;A Veil;J Cortes;H Kantarjian;S Waxman Blood 84(10)(Suppl.1)(#1500):379a

An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22).

JR Downing;DR Head;AM Curcio-Brint;MG Hulshof;TA Motroni;SC Raimondi;AJ Carroll;HA Drabkin;CL Willman;KS Theil;CI Civin;P Erikson Blood 81(11):2860-2865

HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.

SP Hunger;DC Tkachuk;MD Amylon;MP Link;AJ Carroll;Jl Welborn;CL Willman;ML Cleary Blood 81(12):3197-3203

Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).

AA Scott;DR Head;K Theil;LM Chen;MH Whittaker;CL Willman International Academy of Pathology 68:100A(#575)

Clinical and molecular characterization of the acute promyelocytic leukemia (APL) associated with the t(11;17) and PLZF-RAR fusion.

Z Chen;JD Licht;A Zelent;SJ Chen;A Chen;Y Wu;WH Miller Jr;A Zelenetz;A Goy;A DeBlasio;A Scott;C Willman;D Head;C Chomienne;F Guidez;S Waxman Blood 82(10)(Suppl.1):(#432)

Interferon regulatory factor-1 (IRF-1): A candidate tumor suppressor gene on chromosome 5q31-1 deleted in leukemia and myelodysplasia (MDS) with del (5q) or translocation of 5q31.

CL Willman;C Sever;M Pallavicini;H Harada;N Tanaka;M Slovak;A List;H Yamamoto;K Harada;T Taniguchi Blood 80:74a(#286)

The human cell cycle gene CDC25C maps to chromosome 5q31.1 within 100 KB of interferon regulatory factor-1 (IRF-1) in the critical region deleted in myelodysplasia (MDS) and leukemia with 5q abnormalities.

C Sever;CL Willman;H Harada;T Taniguchi;W Kuo;M Pallavicini;M Slovak;T Meeker Blood 80(10)-Suppl.1:195a(#769)

Evaluation of the proliferative fraction of cytogenetically normal and aberrant hemopoietic subpopulations in acute myeloid leukemia (AML and myelodysplasia (MDS).

TI George;B Mehrotra;CL Willman;PI Greenberg;MG Pallavicini Blood 80(10)-Suppl.1:30a

Variable frequency of cytogenetically aberrant cells in the stem cell compartment and hemopoietic lineages in acute myeloid leukemia (AML) and myelodysplasia (MDS).

B Mehrotra;C Mar;WL Kuo;CL Willman Blood 80(10)-Suppl.1:30a

Precise localization of the long arm breakpoint of the inv(16) of ANNL M4Eo and progress towards cloning this breakpoint.

D Callen;B Kuss;CL Willman;H Eyre;J Nancarrow;N Lapsys;RI Richards;GR Sutherland Am J Human Genetics 51(4):57A